Accessibility Menu
Precigen logo

Precigen(NASDAQ) PGEN

Current Price$5.41
Market Cap$1.93BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2013)-78%
5 Year-0%
1 Year+238%
1 Month+0%
Precigen last closing stock price
MetricPriceDate
Last closeUSD 5.402026-07-24
Precigen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+9.09%USD 4.952026-07-17
1 month+0%USD 5.402026-06-24
3 month+30.75%USD 4.132026-04-24
Year to date+29.19%USD 4.182025-12-31
1 year+237.5%USD 1.602025-07-24
3 year+332%USD 1.252023-07-25
5 year-0.18%USD 5.412021-07-23
Since inception-78.09%USD 24.652013-08-08

Precigen Financials at a Glance

Market Cap

$1.93BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$31.60M

Net Income (TTM)

-$204.42M

EPS (TTM)

-$1.24

P/E Ratio

-4.36

Dividend

$0.00

Beta (Volatility)

1.79 (High)

Price

$5.41

Volume

121,284

Open

$5.62

Previous Close

$5.41

Daily Range

$5.29 - $5.62

52-Week Range

$1.54 - $6.04

Estimated Earnings Date

Aug 11, 2026

PGEN News

SellAlert-Red.png

What Does the Sale of Precigen Shares Worth $1.1 Million by the CFO Mean for Investors?

Robert IzquierdoJul 15, 2026
SellAlert-Red.png

Is Precigen (PGEN) a Stock to Sell After Its CFO Let Go of 41,000 Shares?

Cory RenauerJun 12, 2026
BuyAlert-Purple.png

Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet?

Jonathan PoncianoDec 2, 2025
institutional.png

Patient Capital Bets Big on Precigen (PGEN) By Acquiring 10.2 Million Shares

Cory RenauerNov 1, 2025
investors-picking-stocks-on-computer-getty

These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts

Cory RenauerSep 7, 2025
investor ponders phone and laptop stock charts

2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 Years

Alex CarchidiMar 17, 2023
Test tubes

Why Precigen Stock Is Skyrocketing Today

Keith SpeightsOct 9, 2020
Balance Sheet

Here's Why Intrexon Jumped 58% in June

Brian Orelli, PhDJul 9, 2019
Page 1

PGEN: Motley Fool Moneyball Superscore

53

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Precigen

Precigen creates special medicines for people with hard-to-treat diseases. These treatments help the body's natural defenses fight cancer and infections. Their newest product helps patients breathe better by treating throat tumors.

What Precigen Makes

  • Papzimeos: A treatment for adults with tumors in the throat caused by certain chronic viral infections.
  • AdenoVerse Platform: A system that uses engineered viruses to deliver therapeutic genetic material into a patient's cells.
  • UltraCAR-T: A technology used to create personalized immune cells for cancer patients in a single day.
  • UltraPorator: A specialized device designed to manufacture cell therapies quickly at a lower cost.

Moving From Lab to Market

  • Received full FDA approval for Papzimeos in August 2025 to treat adults with recurrent respiratory papillomatosis.
  • Partnered with Eversana to manage the commercial launch and sales strategy in the United States.
  • Submitted a Marketing Authorization Application to the European Medicines Agency in November 2025 to expand into international markets.
  • Closed the operations of the Precigen ActoBio subsidiary in 2024 to focus resources on core clinical programs.

What Makes the Tech Different

The company uses a proprietary overnight process to create personalized cancer treatments directly at hospital sites. Their delivery technology can carry large amounts of genetic material and allows for repeated doses without losing effectiveness.

Tracking the Financial Performance

  • Revenue rose to $4.6 million in Q4 2025, up 283.6% from Q4 2024.
  • Gross profit reached $2.7 million in Q4 2025, up from $21,000 in the previous year.
  • Operating losses narrowed to $21.7 million in Q4 2025, a 24% improvement from Q4 2024.
  • Net loss deepened to $23.5 million in Q4 2025, worsening by 19.1% compared to Q4 2024.

The Bottom Line

Precigen has transitioned from a research-focused organization to a commercial-stage biotechnology firm with its first approved product. Its shift toward rapid, decentralized manufacturing and targeted viral delivery supports its current focus on oncology and infectious diseases.

AI Generated • Apr 30, 2026

Industry

Biotechnology

Sector

Health Care

Employees

160

CEO

Helen Sabzevari, PhD

Website

www.precigen.com

Headquarters

Germantown, MD 20876, US

PGEN Financials

Key Financial Metrics (TTM)

Gross Margin

75.63%

Operating Margin

-297.21%

Net Income Margin

-646.99%

Return on Equity

-1768.51%

Return on Capital

-89.43%

Return on Assets

-147.46%

Earnings Yield

-22.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.93BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

356.51M

Volume

121.28K

Avg. Volume

4.51M

Financials (TTM)

Gross Profit

$23.90M

Operating Income

-$93.91M

EBITDA

-$195.19M

Operating Cash Flow

-$115.33M

Capital Expenditure

-$2.24M

Free Cash Flow

-$117.57M

Cash & ST Invst.

$56.25M

Total Debt

$98.25M

Precigen Performance Analysis

Precigen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 26,909,00088.6%
20232023-12-31USD 6,225,000-76.9%
20242024-12-31USD 3,925,000-36.9%
20252025-12-31USD 9,684,000146.7%
Precigen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-36.2%
Q32025-09-30241.4%
Q42025-12-3156.2%
Q12026-03-31409.4%
Precigen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.33-28.9%
20232023-12-31USD -0.3918.4%
20242024-12-31USD -0.4720.2%
20252025-12-31USD -1.37191.1%
Precigen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3050.1%
Q32025-09-30-1123.6%
Q42025-12-3194.0%
Q12026-03-3161.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$23.25M

+1633.9%

Gross Profit

$20.38M

+26221.8%

Gross Margin

87.63%

N/A

Market Cap

$1.93BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.03M

N/A

Employees

160

N/A

Net Income

-$7.93M

+85.4%

EBITDA

-$3.92M

+92.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$56.25M

-29.9%

Total Debt

$98.25M

+1713.7%

Accounts Receivable

$26.71M

+2409.9%

Inventory

$14.73M

N/A

Long Term Debt

$97.18M

+2064.9%

Short Term Debt

$1.07M

+15.1%

Return on Assets

-1.47%

N/A

Return on Invested Capital

-79.90%

N/A

Free Cash Flow

-$44.09M

-160.1%

Operating Cash Flow

-$43.83M

-168.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AMLXAmylyx Pharmaceuticals, Inc.
$18.41+4.66%
NKTRNektar Therapeutics
$70.73+1.97%
ORICORIC Pharmaceuticals, Inc.
$12.10+11.11%
TRMLTourmaline Bio, Inc.
$47.98+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
FFord Motor Company
$14.37+0.02%
AALAmerican Airlines Group
$14.48+0.07%

Questions About PGEN

What is the current price of Precigen?

Precigen is trading at $5.41 per share.

What is the 52-week range for Precigen?

Over the past 52 weeks, Precigen has traded between $1.54 and $6.04.

How much debt does Precigen have?

As of the most recent reporting period, Precigen reported total debt of $98.25M.

How much cash does Precigen have on hand?

Precigen reported $7.48M in cash and cash equivalents in its most recent financial results.

What is Precigen’s dividend yield?

Precigen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services